

## DAFTAR PUSTAKA

- Ahn, S., Lee, K.Y., Parker, K.K., Shin, K., 2018. Formation of Multi-Component Extracellular Matrix Protein Fibers. *Sci. Rep.* 8: 1–6.
- Al-Azhri, J., Zhang, Y., Bshara, W., Zirpoli, G., Mccann, S.E., Morrison, C.D., et. al., 2017. Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis. *Clin. Cancer Res.* 23: 97–104.
- Allison, K.H., Sam, C.M.E., 2012. Molecular Pathology of Breast Cancer What a Pathologist Needs to Know. *Mol. Diagnostic Consult.* 138: 770–780.
- Anders, C.K., Johnson, R., Litton, J., Phillips, M., Bleyer, A., 2009. Breast Cancer Before Age 40 Years. *YSONC* 36: 237–249.
- Anderson, S.J., Wapnir, I., Dignam, J.J., Fisher, B., Mamounas, E.P., Jeong, J., et. al., 2015. Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast. *J. Clin. Oncol.* 27.
- Anderson, W., Rosenberg, P., Prat, A., Perou, C., Sherman, M., 2014. How Many Etiological Subtypes of Breast Cancer : Two , Three , Four , Or More ? *J. Natl. Cancer Inst.* 106: 1–11.
- Barnato, S.E., Gradishar, W.J., 2015. Biological Subtypes of Breast Cancer, in: Strauss, J., Small, W., Woloschak, G.E. (Eds.), *Medical Radiology*. Springer-Verlag, pp. 1–6.
- Boffa, D.J., Greene, F.L., Stage, T.H.E., Phenomenon, S., 2011. Reacting to Changes in Staging Designations in the 7th Edition of the AJCC Staging Manual. *Ann. Surg. Oncol.* 18: 1–3.
- Bray, F., Ferlay, J., Soerjomataram, I., 2018. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer J. Clin.* 00: 1–31.
- Burstein, H.J., Sun, Y., Dirix, L.Y., Jiang, Z., Paridaens, R., Tan, A.R., et.al., 2015. Neratinib , an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor , in Patients With Advanced ErbB2-Positive Breast Cancer. *J. Clin. Oncol.* 28: 1301–1307.
- Campbell, M.J., Trump, D.L., 2017. Vitamin D Receptor Signaling and Cancer. *Endocrinol. Metab. Clin. NA* 46: 1009–1038.
- Capulli, M., Angelucci, A., Driouch, K., Garcia, T., Clement-lacroix, P., Martella, F., et. al., 2012. J BMR Increased Expression of a Set of Genes Enriched in Oxygen Binding Function Discloses a Predisposition of Breast Cancer Bone Metastases to Generate Metastasis Spread in Multiple Organs. *J. Bone Miner. Res.* 27: 2387–2398.
- Carlson, R.W., Allred, D.C., Anderson, B.O., Burstein, H.J., Carter, W.B., Edge, S.B., et. al., 2011. Invasive Breast Cancer Clinical Practice Guidelines in Oncology. *Natl. Compr. Cancer Netw.* 9: 136–222.
- Carroll, J.S., 2013. Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. *Eur. J. Endocrinology* 175: 61–69.
- Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., et. al., 2015. New horizons in tumor microenvironment biology: challenges and opportunities New

- horizons in tumor microenvironment biology: challenges and opportunities. *BMC Med.* 13: 1–13.
- Choi, W.W.L., Lewis, M.M., Lawson, D., Yin-goen, Q., Birdsong, G.G., Cotsonis, G.A., Cohen, C., Young, A.N., 2005. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. *Mod. Pathol.* 18: 143–152.
- Chung, I., Han, G., Seshadri, M., Gillard, B.M., Yu, W., Foster, B.A., et.al., 2009. Role of Vitamin D Receptor in the Antiproliferative Effects of Calcitriol in Tumor-Derived Endothelial Cells and Tumor Angiogenesis In vivo. *Am. Assoc. Caancer Res.* 69: 1–10.
- Clark, S.E., Warwick, J., Carpenter, R., Bowen, R.L., Duffy, S.W., Jones, J.L., 2010. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. *Br. J. Cancer* 104: 120–127.
- Cockburn, J.G., Hallett, R.M., Gillgrass, A.E., Dias, K.N., Whelan, T., Levine, M.N., et. al., 2016. The effects of lymph node status on predicting outcome in ER + / HER2- tamoxifen treated breast cancer patients using gene signatures. *BMC Cancer* 16: 1–11.
- Colleoni, M., Anders, C.K., 2013. Oncologist Debate: The Biology of Breast Cancer in Young Women Is Unique. *Oncologist* 18: 1–3.
- Comen, E., Norton, L., Massagué, J., 2011. Clinical implications of cancer self-seeding. *Nat. Publ. Gr.* 8: 369–377.
- Dai, D., Zhong, Y., Wang, Z., Yousafzai, N.A., 2019. The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study. *Peer J* 2: 1–14.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., Shi, B., 2015. Breast cancer intrinsic subtype classification, clinical use and future trends. *Am. J. Cancer Res.* 5: 2929–2943.
- Darb-esfahani, S., Denkert, C., Stenzinger, A., Salat, C., Sinn, B., Schem, C., et. al., 2016. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline / taxane- based chemotherapy. *Oncotarget* 7: 67686–67698.
- Denton, A.E., Roberts, E.W., Fearon, D.T., 2018. Stromal Cells in the Tumor Microenvironment. *Springer* 99–114.
- Ditsch, N., Toth, B., Mayr, D., Lenhard, M., Gallwas, J., Dannecker, C., et. al., 2012. The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer. *J. Histochem. Cytochem.* 60: 121–129.
- Ditsch, N., Toth, B., Mayr, D., Lenhard, M., Gallwas, J., Dannecker, C., et.al., 2011. The Association between Vitamin D Receptor Expression and Prolonged Overall The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer. *J. Histochem. Cytochem.* 60: 121–129.
- Dunnwald, L.K., Rossing, M.A., Li, C.I., 2007. Research article Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Res.* 9: 1–10.
- Eliyatkin, N., Yalçın, E., Zengel, B., Aktaş, S., Vardar, E., 2015. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. *J. Breast Heal.* 11: 59–66.
- Ellis, I., Collins, L., Ichihara, S., MacGrogan, S., 2012. CHAPTER 1 WHO

- histological classification of tumours of the breast, 4th Editio. ed, WHO Classification of Tumours of the Breast Fourth Edition. International Agency for Research on Cancer, Lyon.
- Elston, C.W., Ellis, O., 1991. Pathological prognostic factors in breast cancer . I . The value of histological grade in breast cancer : experience from a large study with long-term follow-up. *Histopathology* 19: 403–410.
- Fallahpour, S., Navaneelan, T., Borgo, A., 2017. Breast cancer survival by molecular subtype: a population based analysis of cancer registry data. *CMAJ* 5: 734–739.
- Ferrer-mayorga, G., Gómez-lópez, G., Barbáchano, A., Fernández-barral, A., Peña, C., Pisano, D.G., et.al., 2017. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. *Endocrinol. Metab. Clin. North Am.* 46: 1449–1462.
- Franco, O.E., Shaw, A.K., Strand, D.W., Hayward, S.W., 2010. Seminars in Cell & Developmental Biology Cancer associated fibroblasts in cancer pathogenesis. *Semin. Cell Dev. Biol.* 21: 33–39.
- Genova, C., Rijavec, E., Grossi, F., 2017. Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer : can we use enemy territory at our advantage ? *J. Thorac. Dis.* 9: 4300–4304.
- Gnant, M., Thomssen, C., Gelber, R.D., Gnant, M., Goodwin, P., Harris, J.R., 2011. Breast Care St . Gallen 2011 : Summary of the Consensus Discussion. *Breast Care* 6: 136–141.
- Gocek, E., Studzinski, P., 2010. Vitamin D and differentiation in cancer. *Crit. Rev. Clin. Lab. Sci.* 46: 1–31.
- Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thu, B., 2011. Strategies for subtypes — dealing with the diversity of breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann. Oncol.* 22: 1736–1747.
- Gombart, A.F., Luong, Q.T., Koeffler, H.P., 2006. Vitamin D Compounds : Activity Against Microbes and Cancer. *Anticancer Res.* 2542: 2531–2542.
- Gy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B., Pusztai, L., 2015. Multigene prognostic tests in breast cancer : past , present , future. *Breast Cancer Res.* 17: 1–7.
- Hammond, M.E., Love, R., Mangu, P.B., Mcshane, L., Miller, K., Osborne, C.K., et.al., 2010. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *J. Clin. Oncol.* 28: 2784–2795.
- Han, J., Jiang, Y., Zhang, C., Pang, D., Zhang, M., Wang, Y., 2011. Clinicopathologic characteristics and prognosis of young patients with breast cancer. *The Breast* 20: 370–372.
- Hoyer-Hansen, M., Bastholm, L., Mathiasen, I.S., Elling, F., 2005. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. *Cell Death Differ.* 12: 1297–1309.
- Hung, M., Xu, J., Nielson, D., Bounsanga, J., Gu, Y., Hansen, A.R., Voss, M.W., 2018. Breast Cancer Evaluating the Prediction of Breast Cancer Survival Using Lymph Node Ratio. *J. Breast Cancer* 21: 315–320.
- Huss, L., Butt, S.T., Borgquist, S., Elebro, K., Sandsveden, M., Rosendahl, et. al., 2019. Vitamin D receptor expression in invasive breast tumors and breast cancer

- survival. *Breast Cancer Res.* 21: 1–13.
- Iqbal, N., Iqbal, N., 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers : Overexpression and Therapeutic Implications. *Mol. Biol. Int.* 2014: 1–9.
- Joseph, C., Papadaki, A., Althobiti, M., M, A., Aleskandarani, M., 2018. Breast cancer intratumour heterogeneity: current status and clinical implications. *Histopathology* 5: 0–3.
- Kamińska, M., Ciszewski, T., Łopacka-szatan, K., Miotła, P., Starosławska, E., 2015. Review paper Breast cancer risk factors. *Menopausal Rev.* 14: 196–202.
- Kao, J., Salari, K., Bocanegra, M., Choi, Y., Girard, L., Gandhi, J., et. al., 2009. Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. *PLoS One* 4.
- Kasangian, A.A., Gherardi, G., Biagioli, E., Torri, V., Moretti, A., Bernardin, E., et.al., 2017. The prognostic role of tumor size in early breast cancer in the era of molecular biology. *PLoS One* 12: 1–12.
- Keam, B., Im, S., Lee, K., Han, S., Oh, D., Kim, J.H., Lee, S., Han, W., Kim, D., Kim, T., Park, I.A., Noh, D., 2011. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Res.* 13: 1–7.
- Kilickap, S., Kaya, Y., Yucel, B., Tuncer, E., Akgul, N., Elagoz, S., 2014. Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer. *Asian Pacific J. Cancer Prev.* 15: 1381–1385.
- Kim, J., Kim, J., Jung, E.J., Kwag, S.J., Park, J., Park, T., Jeong, S., Jeong, C., Ju, Y., Lee, Y., Hong, S., 2018. The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis. *Korean J. Clin. Oncol.* 14: 43–47.
- Kong, F., L, L., Wang G, et al, 2018. VDR signaling inhibits cancer- associated-fibroblasts ' release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. *Gut* 0: 2–3.
- Kumar V, Abbas AK, Fausto N, Aster JC. 2010. Robbins and Coltran, Pathologic Basis of Disease. 8th eds, Elsevier Saunders
- Lee, H., Han, W., 2014. Breast Cancer Unique Features of Young Age Breast Cancer and Its Management. *J. Breast Cancer* 17: 301–307.
- Leong, A.S., 2011. The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. *Pathobiology* 2310: 99–114.
- Li, A., Zhou, S., Li, M., Xu, Y., Shui, R., Yu, B., 2015. Clinicopathologic Characteristics of Oestrogen Receptor-Positive / Progesterone Receptor-Negative / Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status : A Large Population-Based Study from China. *PLoS One* 10: 1–12.
- Liedtke, C., Rody, A., Gluz, O., Baumann, K., 2015. The prognostic impact of age in different molecular subtypes of breast cancer. *Breast Cancer Res. Treat.* 152: 667–673.
- Lu, P., Weaver, V.M., Werb, Z., 2012. The extracellular matrix : A dynamic niche in cancer progression. *J. Cell Biol.* 196: 395–406.
- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., Basso, S.M.M., 2013. Treatment of Estrogen Receptor-Positive Breast Cancer. *Curr. Med. Chem.* 20: 596–604.

- Maggard, M.A., Connell, J.B.O., Lane, K.E., Liu, J.H., Etzioni, D.A., Ko, C.Y., 2003. Do Young Breast Cancer Patients Have Worse Outcomes ? *J. Surg. Res.* 113: 109–113.
- Makki, J., 2015. Diversity of Breast Carcinoma : Histological Subtypes and Clinical Relevance. *Clin. Med. Insight Pathol.* 8: 23–31.
- Mcgregor, N., Axelrod, R., Axelrod, D.E., 2008. Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel. *Transl. Oncol.* 1: 158–164.
- Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., 2001. HER2 as a Prognostic Factor in Breast Cancer. *Oncology* 61: 67–72.
- Meric-bernstam, F., Hung, M., 2006. Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy. *Mol. Pathways* 12: 6326–6331.
- Miguel, J., Pascual, T., Fernández-martínez, A., Brasó-maristany, F., Gomis, R.R., Perou, C.M., 2018. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. *Cancer Treat. Rev.* 67: 63–70.
- Mitri, Z., Constantine, T., Regan, R.O., 2012. The HER2 Receptor in Breast Cancer : Pathophysiology , Clinical Use , and New Advances in Therapy. *Chemotherapy Res. Pract.* 2012: 1–7.
- Narod, S.A., 2012. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. *Curr. Oncol.* 19: 249–253.
- Narvaez, C.J., Matthews, D., Laporta, E., Simmons, K.M., Beaudin, S., 2014. The impact of vitamin D in breast cancer : genomics , pathways , metabolism. *Front. Physiol.* 5: 1–10.
- Nishida, N., 2006. Angiogenesis in cancer. *Vasc. Health Risk Manag.* 2: 213–219.
- Noman, M.Z., 2012. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. *Front. Immunol.* 3: 1–10.
- Of, M., Metastases, B., Breast, O.F., 2010. NIH Public Access. *Endocr. Relat. Cancer* 16: 703–713.
- Ovcaricek, T., Frkovic, S.G., Matos, E., Mozina, B., Borstnar, S., 2011. Triple negative breast cancer – prognostic factors and survival. *Radiol. Oncol.* 45: 46–52.
- Petrova, V., Annicchiarico-petruzzelli, M., Melino, G., Amelio, I., 2018. The hypoxic tumour microenvironment. *Oncogenesis* 7: 1–13.
- Pickholtz, I., Saadyan, S., Keshet, G.I., Wang, V.S., Bouwman, P., Jonkers, J., et.al., 2014. Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells . *Oncotarget* 5: 11827–11847.
- Place, A.E., Huh, S.J., Polyak, K., 2011. The microenvironment in breast cancer progression : biology and implications for treatment.
- Polyak, K., 2011. Introduction Heterogeneity in breast cancer. *J. Clin. Invest.* 121: 3786–3788.
- Prior, L., Lim, M., Ward, C., Featherstone, H., Murray, H., Arcy, C.D., Crown, J., Gullo, G., 2017. Metastatic HER2 + Breast Cancer : A Potentially Curable Disease ? Case Presentation. *Cureus* 9: 1–19.
- Rahmawati, Y., Setyawati, Y., Widodo, I., Ghozali, A., Purnomosari, D., 2017. Hubungan Antara Usia dan Ukuran Tumor dengan Subtipe Molekuler Karsinoma Payudara di RSUP Dr. Sardjito Yogyakarta. *Asian Pacific J. Cancer*

*Prev.* 19: 161–166.

- Rakha, E.A., Reis-filho, J.S., Baehner, F., Dabbs, D.J., Decker, T., Eusebi, V., et.al., 2010. Breast cancer prognostic classification in the molecular era : the role of histological grade. *Breast Cancer Res.* 12: 1–12.
- Saedi, H.S., Nasiri, M.G., Shahidsales, S., Taghizadeh, A., 2012. Comparison of Hormone Receptor Status in Primary and Recurrent Breast Cancer. *Iran J. Cancer Prev.* 5: 69–73.
- Sagara, Y., Freedman, R.A., Vaz-luis, I., Mallory, M.A., Wong, S.M., Aydogan, F., Desantis, S., Barry, W.T., Golshan, M., 2016. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ : A Population-Based Longitudinal Cohort Study. *J. Clin. Oncol.* 34: 1–11.
- Samphao, S., D, M., Wheeler, A.J., D, M., Rafferty, E., D, M., Michaelson, J.S., Ph, D., Specht, M.C., D, M., Gadd, et.al., 2009. Diagnosis of breast cancer in women age 40 and younger : delays in diagnosis result from underuse of genetic testing and breast imaging. *Am. J. Surg.* 198: 538–543.
- Santonja, A., Sánchez-muñoz, A., Lluch, A., Chica-, M.R., 2018. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. *Oncotarget* 9: 26406–26416.
- Santos-martínez, N., Díaz, L., Ordaz-rosado, D., García-quiros, J., Barrera, D., Avila, E., Halhali, A., Medina-franco, H., Ibarra-sánchez, M.J., Esparza-lópez, J., Camacho, J., Larrea, F., García-becerra, R., 2014. Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells : A potential new therapeutic approach. *BMC Cancer* 14: 1–10.
- Schatten, H., 2013. Cell and Molecular Biology of Breast Cancer, 1st Editio. ed. Springer US, Columbia.
- Setyawati, Y., Rahmawati, Y., Widodo, I., Ghozali, A., Purnomosari, D., 2018. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. *Asian Pacific J. Cancer Prev.* 19: 1263–1268.
- Shany, S., Sigal-batikoff, I.N.A., Lamprecht, S., 2016. Vitamin D and Myofibroblasts in Fibrosis and Cancer : At Cross-purposes with TGF- $\beta$  / SMAD Signaling. *Anticancer Res.* 6234: 6225–6234.
- Shirinifard, A., Gens, J.S., Zaitlen, B.L., Popławski, N.J., Swat, M., James, A., 2009. 3D Multi-Cell Simulation of Tumor Growth and Angiogenesis. *PLoS One* 4: 1–11.
- Singletary, S.E., 2003. Rating the Risk Factors for Breast Cancer. *Ann. Surg.* 237: 474–482.
- Sotiriou, C., Pusztai, L., 2009. Gene-Expression Signatures in Breast Cancer. *N. Engl. J. Med.* 360: 790–800.
- Soysal, S.D., Tzankov, A., Muenst, S.E., 2015. Role of the Tumor Microenvironment in Breast Cancer. *Pathobiology* 82: 142–152.
- Spill, F., Reynolds, D.S., Kamm, R.D., Zaman, M.H., 2016. ScienceDirect Impact of the physical microenvironment on tumor progression and metastasis. *Curr. Opin. Biotechnol.* 40: 41–48.
- Tesarova, P., 2012. Breast cancer in the elderly-Should it be treated differently? *Reports Pract. Oncol. Radiother.* 18: 26–33.
- Thakkar, A., Buchwald, B.W.M.P.P., Ince, T.A., 2016. Vitamin D and androgen

- receptor-targeted therapy for triple-negative breast cancer. *Breast Cancer Res. Treat.* 157: 77–90.
- Tonello, F., Bergmann, A., Aguiar, S.S. De, Bello, M.A., 2019. Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. *Eur. J. Breast Heal.* 15: 76–84.
- Trivedi, T., Zheng, Y., Fournier, P.G.J., Murthy, S., John, S., Schillo, S., et. al., 2017. The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. *Oncotarget* 8: 26687–26701.
- Valkenburg, K.C., Groot, A.E. De, Pienta, K.C., Sciences, M., 2018. Targeting the tumour stroma to improve cancer therapy. *Nat. Rev. Clin. Oncol.* 15: 366–381.
- Van Asten, K., Sembrouck, L., Olbrecht, S., 2018. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive , HER-2 Negative Breast Cancer. *Oncologist* 23: 1–7.
- Vlieghere, E. De, Verset, L., Demetter, P., Bracke, M., Wever, O. De, Wever, O. De, 2015. Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. *Virchows Arch.* 467: 367–382.
- Wang, Y., Zhu, J., Deluca, H.F., 2012. Where is the vitamin D receptor? *Arch. Biochem. Biophys.* 523: 123–133.
- Weitsman, G., Liberman, U., Ravid, A., Koren, R., 2003. Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. *Ann. N. Y. Acad. Sci.* 1010: 437–40.
- Welsh, J., 2007. Targets of Vitamin D Receptor Signaling in the Mammary Gland. *J. Bone Miner. Res.* 22: V86–V90.
- Widodo, I., Dwianingsih, E.K., Anwar, S.L., Ediati, F., Utoro, T., Aryandono, T., 2017. Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes. *Asian Pacific J. Cancer Prev.* 18: 1251–1256.
- Widodo, I., Dwianingsih, E.K., Triningsih, E., Utoro, T., 2014. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pacific J. Cancer Prev.* 15: 6109–6113.
- Wolff, A.C., Hammond, M.E.H., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., et. al., 2007. American Society of Clinical Oncology /College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *J. Clin. Oncol.* 25: 118–145.
- Wu, X., Hu, W., Lu, L., Zhao, Y., Zhou, Y., Xiao, Z., Zhang, L., Zhang, H., Li, X., Li, W., Wang, S., Hin, C., Shen, J., 2018. Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. *Acta Pharm. Sin. B* 9: 203–219.
- Yao, N., Song, Z., Wang, X., Yang, S., Song, H., 2017. Breast Cancer Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. *J. Breast Cancer* 20: 160–169.
- Yuan, Y., Jiang, Y., Sun, C., Chen, Q., 2016. Role of the tumor microenvironment in tumor progression and the clinical applications ( Review ). *Oncol. Rep.* 35: 2499–2515.
- Zhang, X., Harbeck, N., Jeschke, U., Doisneau, S., 2016. Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. *J. Cancer Res. Clin. Oncol.* 143.

- Zheng, K., Tan, J., Li, F., Li, H., 2018. Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients. *Transl. Oncol.* 11: 1023–1033.
- Zheng, Y., Trivedi, T., Lin, R.C.Y., Fong-ye, C., Nolte, R., Manibo, J., Chen, Y., Hossain, M., Horas, K., Dunstan, C., Zhou, H., Seibel, M.J., 2017. Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt /  $\beta$  -catenin signaling. *Bone Res.* 5: 1–12.